HRTS Tema Heart & Health ETF

ETF on NASDAQ (US) · Actively managed · Listing

Form N-PORT Aug 31, 2026 vs May 31, 2026 Filed with the SEC Oct 30, 2026
Book +7% $51.9M → $55.6M
Line items (May 31, 2026: 45) 46
In top 10 48%
Largest holding: Eli Lilly and Company ($6.18M) 11.1%
Portfolio date Aug 31, 2026
New / increased 3 / 7
Reduced / closed 35 / 2
Unchanged 0
−45%

Most notable sale · Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited cut by 45%

Shares went from 30,273 to 16,554 ($1.07M → $597K). Now 1.1% of the portfolio. Estimated trade $495K.

New

Most notable buy · Kodiak Sciences Inc

New position in Kodiak Sciences Inc

33,234 shares worth $1.24M. Now 2.2% of the portfolio.

Largest holding: Eli Lilly and Company, cut 1%, 5,343 shares ($6.18M).

Eli Lilly and Company: 11.1% Thermo Fisher Scientific Inc: 5.1% UnitedHealth Group Incorporated: 5.0% Novo Nordisk A/S: 4.8% Merck & Company, Inc.: 4.3% Johnson & Johnson: 3.9% Roche Holding AG: 3.8% Revolution Medicines, Inc.: 3.7% Cytokinetics, Incorporated: 3.5% BridgeBio Pharma, Inc.: 3.2% The other 36 positions: 51.5% $55.6M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $6.18M · −1% sh 11.1%
Thermo Fisher Scientific Inc TMO $2.85M · +10% sh 5.1%
UnitedHealth Group Incorporated UNH $2.80M · +1% sh 5.0%
Novo Nordisk A/S NOVOB $2.66M · −1% sh 4.8%
Merck & Company, Inc. MRK $2.40M · −13% sh 4.3%
Johnson & Johnson JNJ $2.17M · −1% sh 3.9%
Roche Holding AG RHHBY $2.09M · −12% units 3.8%
Revolution Medicines, Inc. RVMD $2.05M · −9% sh 3.7%
Cytokinetics, Incorporated CYTK $1.96M · +62% sh 3.5%
BridgeBio Pharma, Inc. BBIO $1.77M · +14% sh 3.2%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.

Healthcare: 93.0% Unclassified: 7.0% 1 sectors
Sectors % of holdings value
Healthcare 93.0%
Unclassified 7.0%
Drug Manufacturers - General: 33.8% Biotechnology: 33.4% Medical Devices: 13.8% Medical Instruments & Supplies: 5.1% Healthcare Plans: 5.0% Medical Distribution: 1.9% Unclassified: 7.0% 6 industries
Industries % of holdings value
Drug Manufacturers - General 33.8%
Biotechnology 33.4%
Medical Devices 13.8%
Medical Instruments & Supplies 5.1%
Healthcare Plans 5.0%
Medical Distribution 1.9%
Unclassified 7.0%
Initiations 3 Value
Kodiak Sciences Inc KOD 2.2% of portfolio $1.24M
Stryker Corporation SYK 1.3% of portfolio $740K
Kailera Therapeutics, Inc. KLRA 0.4% of portfolio $216K
Increases 7 Change
Cytokinetics, Incorporated CYTK $1.31M → $1.96M +62%
Intuitive Surgical, Inc. ISRG $675K → $1.21M 2x
Thermo Fisher Scientific Inc TMO $2.06M → $2.85M +10%
BridgeBio Pharma, Inc. BBIO $1.35M → $1.77M +14%
Alnylam Pharmaceuticals, Inc. ALNY $590K → $618K +31%
Danaher Corporation DHR $1.38M → $1.66M +3%
UnitedHealth Group Incorporated UNH $2.72M → $2.80M +1%
Reductions 35 Change
Teva Pharmaceutical Industries Limited TEVA $1.07M → $597K −45%
Amgen Inc. AMGN $992K → $817K −35%
Regeneron Pharmaceuticals, Inc. REGN $866K → $742K −34%
Merck & Company, Inc. MRK $2.22M → $2.40M −13%
Roche Holding AG RHHBY $2.33M → $2.09M −12%
MBX Biosciences, Inc. MBX $276K → $309K −43%
DexCom, Inc. DXCM $996K → $1.01M −18%
Revolution Medicines, Inc. RVMD $1.73M → $2.05M −9%
Gilead Sciences, Inc. GILD $1.78M → $1.74M −10%
Scholar Rock Holding Corporation SRRK $476K → $351K −36%
AstraZeneca AZN $2.08M → $1.62M −11%
Ionis Pharmaceuticals, Inc. IONS $428K → $146K −57%
Terminations 2 Change
Ascendis Pharma A/S ASND was $393K −100%
Structure Therapeutics Inc. GPCR was $180K −100%

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

Tema Heart & Health ETF (formerly, Tema GLP-1, Obesity & Cardiometabolic ETF) (the "Fund") seeks to provide long-term growth of capital.

Principal investment strategies

Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions ("CDC"). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test. 1 The Fund generally is expected to consist of more than 15 companies but not more than 100 companies. The number of constituents may change depending on the number of companies available for investment that meet the Fund's criteria. To be eligible for inclusion in the Fund, a company must have a market capitalization of at least $100 million and there is no upper limit on the market capitalization of a portfolio company. To be eligible for inclusion in the Fund, a company must have a three-month average daily traded value of at least $500,000. A significant portion of the Fund's assets are expected to be invested in the United States and Europe. The Fund will not engage in currency hedging and is expected to own foreign currency for short periods of time for the purposes of buying and selling non-US listed securities and collecting dividends and/or coupon payments from those securities. The Fund is classified as a "non-diversified" investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), which means that it may invest a high percentage of its assets in a limited number of issuers and sectors. The basic investment philosophy of the Adviser is to seek to invest in growth companies within the aforementioned thematic universe that are attractively valued when compared to their fundamentals and potential for earnings growth. Tema ETF LLC's (the "Adviser"), the Fund's investment adviser, security selection process for identifying companies within the aforementioned theme uses both "top down" idea generation (sector, theme, company research) and "bottom up" security selection (valuation, fundamental, quantitative, qualitative measures) approaches. In practice "top down" idea generation means fundamental sector research, quantitative tools (for example screening based on metrics such as five-year historic revenue growth, margins, or returns on invested capital) and the Adviser's own expertise, are used to narrow down the specific thematic research universe. Once this is defined "bottom up" security analysis involves the Adviser comparing valuation multiples (such as free cash flow yield, price to book ratio and price to earnings ratio or enterprise to total invested capital, among others) to fundamental metrics (such as organic revenue growth, margins, returns on invested capital and equity, among others). Investments are deemed attractively valued when compared to fundamentals if the valuation multiples are below and fundamentals are above either (1) peers (2) the companies own historic averages (3) or prospective forecasts (as determined by the Adviser).

Management and Contact

Adviser
Tema ETFs LLC
Sub-adviser
Tidal Investments LLC
Portfolio managers

David Song,Yuri Khodjamirian and Mauritis Pot (all since inception, November 2023).

Sub-Adviser – Tidal Investments LLC .

Portfolio Managers – Qiao Duan and Andy Hicks (since February 2026.

Phone
1.888.744.1377

Track Record as of Feb 28, 2026

1 Year Since Inception
Return Before Taxes 23.64% 16.18%
Return After Taxes on Distributions 23.24% 15.70%
Return After Taxes on Distributions and Sale of Fund Shares 14.27% 12.43%
S&P 500 Total Return Index 17.88% 23.00%

Holdings as of Aug 31, 2026

46 lines, 43 linked, weights sum to 99.92% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
Eli Lilly & Co LLY US5324571083 Equity 5,343 −70 11.11% $ 6.18M
Thermo Fisher Scientific Inc TMO US8835561023 Equity 4,616 +431 5.12% $ 2.849M
UnitedHealth Group Inc UNH US91324P1021 Equity 7,195 +36 5.04% $ 2.802M
Novo Nordisk A/S NOVOB DK0062498333 Equity 58,624 −831 4.79% $ 2.664M
Merck & Co Inc MRK US58933Y1055 Equity 16,233 −2,439 4.31% $ 2.399M
Johnson & Johnson JNJ US4781601046 Equity 8,166 −108 3.90% $ 2.171M
Roche Holding AG
RHHBY US7711951043 Equity 38,978 −5,560 3.76% $ 2.093M
Revolution Medicines Inc RVMD US76155X1000 Equity 9,951 −1,020 3.68% $ 2.046M
Cytokinetics Inc CYTK US23282W6057 Equity 27,649 +10,580 3.53% $ 1.961M
Bridgebio Pharma Inc BBIO US10806X1028 Equity 23,113 +2,786 3.18% $ 1.77M
Gilead Sciences Inc GILD US3755581036 Equity 11,884 −1,377 3.13% $ 1.739M
Abbott Laboratories ABT US0028241000 Equity 15,601 −208 3.10% $ 1.722M
Vertex Pharmaceuticals Inc VRTX US92532F1003 Equity 3,079 −319 3.02% $ 1.677M
Danaher Corp DHR US2358511028 Equity 7,756 +199 2.98% $ 1.656M
AstraZeneca PLC AZN GB0009895292 Equity 9,969 −1,209 2.91% $ 1.617M
Novartis AG
NOVN CH0012005267 Equity 10,564 −1,063 2.90% $ 1.611M
AbbVie Inc ABBV US00287Y1091 Equity 5,088 −626 2.35% $ 1.305M
Bristol-Myers Squibb Co BMY US1101221083 Equity 18,719 −220 2.25% $ 1.251M
Kodiak Sciences Inc KOD US50015M1099 Equity 33,234 new +33,234 2.23% $ 1.241M
Intuitive Surgical Inc ISRG US46120E6023 Equity 3,200 +1,610 2.17% $ 1.206M
Medtronic PLC MDT IE00BTN1Y115 Equity 13,029 −174 2.12% $ 1.181M
McKesson Corp MCK US58155Q1031 Equity 1,182 −14 1.88% $ 1.046M
Dexcom Inc DXCM US2521311074 Equity 11,085 −2,427 1.82% $ 1.009M
Amgen Inc AMGN US0311621009 Equity 1,901 −1,045 1.47% $ 817.202K
Madrigal Pharmaceuticals Inc MDGL US5588681057 Equity 1,499 −20 1.46% $ 809.505K
Edwards Lifesciences Corp EW US28176E1082 Equity 8,572 −1,916 1.40% $ 777.909K
Regeneron Pharmaceuticals Inc REGN US75886F1075 Equity 929 −479 1.34% $ 742.345K
Stryker Corp SYK US8636671013 Equity 2,284 new +2,284 1.33% $ 739.559K
Boston Scientific Corp BSX US1011371077 Equity 15,214 −71 1.32% $ 734.836K
Alnylam Pharmaceuticals Inc ALNY US02043Q1076 Equity 2,566 +612 1.11% $ 617.611K
Teva Pharmaceutical Industries TEVA US8816242098 Equity 16,554 −13,719 1.07% $ 596.772K
Chugai Pharmaceutical Co Ltd 4519 JP3519400000 Equity 13,731 −184 1.07% $ 594.193K
Xenon Pharmaceuticals Inc XENE CA98420N1050 Equity 8,283 −110 0.90% $ 498.802K
Arrowhead Pharmaceuticals Inc ARWR US04280A1007 Equity 5,263 −1,977 0.78% $ 433.619K
Scholar Rock Holding Corp SRRK US80706P1030 Equity 6,177 −3,470 0.63% $ 350.854K
Stoke Therapeutics Inc STOK US86150R1077 Equity 9,917 −132 0.56% $ 309.41K
MBX Biosciences Inc MBX US55287L1017 Equity 5,010 −3,751 0.56% $ 308.616K
Viking Therapeutics Inc VKTX US92686J1060 Equity 8,426 −112 0.50% $ 276.204K
Insulet Corp PODD US45784P1012 Equity 1,827 −1,008 0.49% $ 271.602K
Gubra A/S GUBRA DK0062266474 Equity 4,429 −58 0.47% $ 261.11K
Insmed Inc INSM US4576693075 Equity 2,038 −1,411 0.45% $ 248.269K
Zealand Pharma A/S ZEAL DK0060257814 Equity 5,223 −70 0.44% $ 243.479K
Kailera Therapeutics Inc KLRA US4829311020 Equity 14,039 new +14,039 0.39% $ 216.201K
First American Treasury Obliga
FXFXX US31846V3289 Money market 195,957.05 −177,539.65 0.35% $ 195.957K
Intellia Therapeutics Inc NTLA US45826J1051 Equity 13,708 −184 0.31% $ 174.503K
Ionis Pharmaceuticals Inc IONS US4622221004 Equity 2,427 −3,172 0.26% $ 146.494K

Trades May 31, 2026 to Aug 31, 2026

Holding Ticker Action Before After Change Value
Kodiak Sciences Inc KOD New — 33,234 +33,234 $ 1.241M
Cytokinetics Inc CYTK Bought 17,069 27,649 +10,580 $ 750.228K
Stryker Corp SYK New — 2,284 +2,284 $ 739.559K
Intuitive Surgical Inc ISRG Bought 1,590 3,200 +1,610 $ 606.745K
Teva Pharmaceutical Industries TEVA Sold 30,273 16,554 −13,719 $ -494.57K
Amgen Inc AMGN Sold 2,946 1,901 −1,045 $ -449.225K
Ascendis Pharma A/S ASND Closed 1,755 — −1,755 $ -393.313K
Regeneron Pharmaceuticals Inc REGN Sold 1,408 929 −479 $ -382.759K
Merck & Co Inc MRK Sold 18,672 16,233 −2,439 $ -360.387K
Roche Holding AG
RHHBY Sold 44,538 38,978 −5,560 $ -298.572K
Thermo Fisher Scientific Inc TMO Bought 4,185 4,616 +431 $ 265.97K
MBX Biosciences Inc MBX Sold 8,761 5,010 −3,751 $ -231.062K
Dexcom Inc DXCM Sold 13,512 11,085 −2,427 $ -221.003K
Kailera Therapeutics Inc KLRA New — 14,039 +14,039 $ 216.201K
Bridgebio Pharma Inc BBIO Bought 20,327 23,113 +2,786 $ 213.38K
Revolution Medicines Inc RVMD Sold 10,971 9,951 −1,020 $ -209.681K
Gilead Sciences Inc GILD Sold 13,261 11,884 −1,377 $ -201.51K
Scholar Rock Holding Corp SRRK Sold 9,647 6,177 −3,470 $ -197.096K
AstraZeneca PLC AZN Sold 11,178 9,969 −1,209 $ -196.091K
Ionis Pharmaceuticals Inc IONS Sold 5,599 2,427 −3,172 $ -191.462K
Structure Therapeutics Inc GPCR Closed 4,583 — −4,583 $ -180.295K
Edwards Lifesciences Corp EW Sold 10,488 8,572 −1,916 $ -173.877K
Vertex Pharmaceuticals Inc VRTX Sold 3,398 3,079 −319 $ -173.702K
Insmed Inc INSM Sold 3,449 2,038 −1,411 $ -171.888K
Arrowhead Pharmaceuticals Inc ARWR Sold 7,240 5,263 −1,977 $ -162.885K
Novartis AG
NOVN Sold 11,627 10,564 −1,063 $ -162.09K
AbbVie Inc ABBV Sold 5,714 5,088 −626 $ -160.519K
Insulet Corp PODD Sold 2,835 1,827 −1,008 $ -149.849K
Alnylam Pharmaceuticals Inc ALNY Bought 1,954 2,566 +612 $ 147.302K
Eli Lilly & Co LLY Sold 5,413 5,343 −70 $ -80.971K
Danaher Corp DHR Bought 7,557 7,756 +199 $ 42.498K
Novo Nordisk A/S NOVOB Sold 59,455 58,624 −831 $ -37.757K
Johnson & Johnson JNJ Sold 8,274 8,166 −108 $ -28.712K
Abbott Laboratories ABT Sold 15,809 15,601 −208 $ -22.955K
Medtronic PLC MDT Sold 13,203 13,029 −174 $ -15.773K
Bristol-Myers Squibb Co BMY Sold 18,939 18,719 −220 $ -14.698K
UnitedHealth Group Inc UNH Bought 7,159 7,195 +36 $ 14.019K
McKesson Corp MCK Sold 1,196 1,182 −14 $ -12.394K
Madrigal Pharmaceuticals Inc MDGL Sold 1,519 1,499 −20 $ -10.801K
Chugai Pharmaceutical Co Ltd 4519 Sold 13,915 13,731 −184 $ -7,962.39
Xenon Pharmaceuticals Inc XENE Sold 8,393 8,283 −110 $ -6,624.20
Stoke Therapeutics Inc STOK Sold 10,049 9,917 −132 $ -4,118.40
Viking Therapeutics Inc VKTX Sold 8,538 8,426 −112 $ -3,671.36
Boston Scientific Corp BSX Sold 15,285 15,214 −71 $ -3,429.30
Gubra A/S GUBRA Sold 4,487 4,429 −58 $ -3,419.37
Zealand Pharma A/S ZEAL Sold 5,293 5,223 −70 $ -3,263.18
Intellia Therapeutics Inc NTLA Sold 13,892 13,708 −184 $ -2,342.32

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up